Your browser doesn't support javascript.
loading
SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models.
Shomali, Maysoun; Cheng, Jane; Sun, Fangxian; Koundinya, Malvika; Guo, Zhuyan; Hebert, Andrew T; McManus, Jessica; Levit, Mikhail N; Hoffmann, Dietmar; Courjaud, Albane; Arrebola, Rosalia; Cao, Hui; Pollard, Jack; Lee, Joon Sang; Besret, Laurent; Caron, Anne; Bangari, Dinesh S; Abecassis, Pierre-Yves; Schio, Laurent; El-Ahmad, Youssef; Halley, Frank; Tabart, Michel; Certal, Victor; Thompson, Fabienne; McCort, Gary; Filoche-Rommé, Bruno; Cheng, Hong; Garcia-Echeverria, Carlos; Debussche, Laurent; Bouaboula, Monsif.
Afiliación
  • Shomali M; Sanofi, Research and Development, Cambridge, Massachusetts maysoun.shomali@sanofi.com.
  • Cheng J; Sanofi, Research and Development, Cambridge, Massachusetts.
  • Sun F; Sanofi, Research and Development, Cambridge, Massachusetts.
  • Koundinya M; Sanofi, Research and Development, Cambridge, Massachusetts.
  • Guo Z; Sanofi, Research and Development, Cambridge, Massachusetts.
  • Hebert AT; Sanofi, Research and Development, Cambridge, Massachusetts.
  • McManus J; Sanofi, Research and Development, Cambridge, Massachusetts.
  • Levit MN; Sanofi, Research and Development, Cambridge, Massachusetts.
  • Hoffmann D; Sanofi, Research and Development, Cambridge, Massachusetts.
  • Courjaud A; Sanofi, Research and Development, Vitry-sur-Seine, France.
  • Arrebola R; Sanofi, Research and Development, Vitry-sur-Seine, France.
  • Cao H; Sanofi, Research and Development, Cambridge, Massachusetts.
  • Pollard J; Sanofi, Research and Development, Cambridge, Massachusetts.
  • Lee JS; Sanofi, Research and Development, Cambridge, Massachusetts.
  • Besret L; Sanofi, Research and Development, Vitry-sur-Seine, France.
  • Caron A; Sanofi, Research and Development, Vitry-sur-Seine, France.
  • Bangari DS; Sanofi, Research and Development, Waltham, Massachusetts.
  • Abecassis PY; Sanofi, Research and Development, Vitry-sur-Seine, France.
  • Schio L; Sanofi, Research and Development, Vitry-sur-Seine, France.
  • El-Ahmad Y; Sanofi, Research and Development, Vitry-sur-Seine, France.
  • Halley F; Sanofi, Research and Development, Vitry-sur-Seine, France.
  • Tabart M; Sanofi, Research and Development, Vitry-sur-Seine, France.
  • Certal V; Sanofi, Research and Development, Vitry-sur-Seine, France.
  • Thompson F; Sanofi, Research and Development, Vitry-sur-Seine, France.
  • McCort G; Sanofi, Research and Development, Vitry-sur-Seine, France.
  • Filoche-Rommé B; Sanofi, Research and Development, Vitry-sur-Seine, France.
  • Cheng H; Sanofi, Research and Development, Cambridge, Massachusetts.
  • Garcia-Echeverria C; Sanofi, Research and Development, Vitry-sur-Seine, France.
  • Debussche L; Sanofi, Research and Development, Vitry-sur-Seine, France.
  • Bouaboula M; Sanofi, Research and Development, Cambridge, Massachusetts.
Mol Cancer Ther ; 20(2): 250-262, 2021 02.
Article en En | MEDLINE | ID: mdl-33310762
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptores de Estrógenos Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptores de Estrógenos Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2021 Tipo del documento: Article